Merck’s molnupiravir 💊 is a potential mutagen

alpha

Health

10/12/2021, 1:20:47 AM




On October 1st an independent advisory board that has been monitoring the COVID-19 Merck’s molnupiravir clinical trial recommended to stop the study early&seek EUA for use in COVID-19 infections. As we previously discussed, Moderna and Pfizer mRNA vaccine components ability to regulate gene expression and disrupt normal cellular processes due to modified nucleosides , Molnupiravir is similarly a synthetic nucleoside derivative with action through introduction of copying errors during RNA replication without complete safety studies and potential mutagenic properties for hosts protein synthesis cells.

Merck has a U.S. government contract to supply 1.7 million courses of molnupiravir at a price of $700 per course.